Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)



Status:Active, not recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 127
Updated:3/10/2019
Start Date:March 27, 2017
End Date:September 30, 2020

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

This is a phase III, randomized, open-label, multicenter, global study to determine the
efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy
(EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line
treatment in patients with extensive-stage small-cell lung cancer.

Primary objective of this study is to assess the efficacy of durvalumab + tremelimumab + EP
treatment compared with EP and the efficacy of durvalumab + EP treatment compared with EP in
terms of OS.

All patients will be randomized in a 1:1:1 ratio in a stratified manner according to the
planned platinum-based therapy for Cycle 1 (cisplatin or carboplatin) to receive treatment
with durvalumab + tremelimumab + EP (Arm 1), durvalumab + EP (Arm 2), or standard of care- EP
(Arm 3). Arm 1 and Arm 2 patients receive the treatment until confirmed disease progression
while Arm 3 patients receive up to 6 cycles of EP and prophylactic cranial irradiation if
clinically indicated, at the Investigators' discretion.Patients who have discontinued
treatment due to toxicity or symptomatic deterioration, clinical progression, or who have
commenced subsequent anticancer therapy will be followed up until confirmed disease
progression and for survival.

Targeted population are adult patients (aged ≥18 years) with histologically or cytologically
documented extensive disease (American Joint Committee on Cancer Stage (7th edition) IV SCLC
[T any, N any,M1 a/b]), or T3-4 due to multiple lung nodules that are too extensive or have
tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.
Patients must have WHO/ECOG performance status of 0 or 1.

Tumor assessments will be performed at Screening as baseline with follow-up at Week 6 ±1 week
from the date of randomization, at Week 12 ±1 week from the date of randomization, and then
every 8 weeks ±1 week until confirmed objective disease progression.

An independent data monitoring committee (IDMC) comprised of independent experts will be
convened to confirm the safety and tolerability of the proposed dose and schedule of
durvalumab ± tremelimumab in combination with platinum based chemotherapy at two early stages
of enrolment.

Inclusion criteria:

1. Histologically or cytologically documented extensive disease. Brain metastases; must
be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1
month prior to study treatment.

2. Suitable to receive a platinum-based chemotherapy regimen as 1st line treatment.

3. Life expectancy ≥12 weeks at Day 1.

4. ECOG 0 or 1 at enrolment.

5. No prior exposure to immune-mediated therapy excluding therapeutic anticancer
vaccines.

Exclusion criteria:

1. Any history of radiotherapy to the chest prior to systemic therapy or planned
consolidation chest radiation therapy (except paliative care outside of the chest).

2. Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical
symptomatology suggesting worsening of PNS

3. Active infection including tuberculosis, HIV, hepatitis B anc C

4. Active or prior documented autoimmune or inflammatory disorders

5. Uncontrolled intercurrent illness, including but not limited to interstitial lung
disease.
We found this trial at
20
sites
1354
mi
from 91732
Rogers, AR
Click here to add this to my saved trials
1969
mi
from 91732
Athens, GA
Click here to add this to my saved trials
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
6113
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
1853
mi
from 91732
Fort Wayne, IN
Click here to add this to my saved trials
1840
mi
from 91732
Grand Rapids, MI
Click here to add this to my saved trials
2283
mi
from 91732
Harrisburg, PA
Click here to add this to my saved trials
840
mi
from 91732
Kennewick, WA
Click here to add this to my saved trials
2451
mi
from 91732
Mineola, NY
Click here to add this to my saved trials
1835
mi
from 91732
Muncie, IN
Click here to add this to my saved trials
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
1335
mi
from 91732
Overland Park, KS
Click here to add this to my saved trials
1659
mi
from 91732
Paducah, KY
Click here to add this to my saved trials
26
mi
from 91732
Santa Monica, CA
Click here to add this to my saved trials
352
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
1313
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
1182
mi
from 91732
Wichita, KS
Click here to add this to my saved trials